HSBC analysts have recently boosted their recommendation on Merck shares (NYSE: MRK) to a Buy rating, moving up from a previous Hold. This upgrade is accompanied by a maintained price target of $130. The analysts base this decision on Merck’s strategic approach towards imminent patent expirations and its robust position in oncology.
Merck’s strategy focuses on extending the earnings potential of its oncology portfolio. This is especially significant given the company’s expertise in oncology and a strong clinical pipeline. As clinical successes become evident, analysts expect increased recognition of Merck’s pipeline value.
In 2025, Merck faces several notable opportunities, the stabilisation of Gardasil’s revenue in China could be a significant contributor, the progress on subcutaneous formulations of Keytruda could provide additional market advantages, and the introduction of Winrevir presents further growth prospects
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
HSBC’s analysis of Merck highlights a balanced view of imminent opportunities and risks. The upgrade to a Buy rating reflects confidence in Merck’s strategic direction and its capacity to manage upcoming challenges effectively. While risks remain, particularly related to its product pipeline and market conditions, Merck’s efforts in oncology and strategic innovations signify positive long-term prospects.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- IG Top-tier regulation – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
